共 50 条
- [21] EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapiesINTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1432 - 1444Jia, YijunLi, XuefeiJiang, TaoZhao, ShaZhao, ChaoZhang, LiminLiu, XiaozhenShi, JinpengQiao, MengLuo, JiaweiLiu, SangtianHan, RuoshuangSu, ChunxiaRen, ShengxiangZhou, Caicun
- [22] The EMT transcription factor TWIST1 mediates resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancerCANCER RESEARCH, 2017, 77Yochum, Zachary A.Wang, HailunCades, Jessica A.Khetarpal, SusheelHuang, Eric H.Tran, Phouc T.Burns, Timothy F.
- [23] Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersCLINICAL CANCER RESEARCH, 2013, 19 (08) : 2240 - 2247Yu, Helena A.Arcila, Maria E.Rekhtman, NatashaSima, Camelia S.Zakowski, Maureen F.Pao, WilliamKris, Mark G.Miller, Vincent A.Ladanyi, MarcRiely, Gregory J.
- [24] Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung CarcinomaCANCER RESEARCH, 2020, 80 (19) : 4224 - 4232Pulido, InesOllosi, StephenAparisi, SalvadorBecker, Jeffrey H.Aliena-Valero, AliciaBenet, MartaRodriguez, Maria L.Lopez, AdrianTamayo-Torres, EvaChulia-Peris, LourdesGarcia-Canaveras, Juan CarlosSoucheray, MargaretDalheim, Annika, VSalom, Juan B.Qiu, WeiKaja, SimonFernandez-Coronado, Javier AlcacerAlandes, SandraAlcacer, JavierAl-Shahrour, FatimaBorgia, Jeffrey A.Juan, OscarNishimura, Michael, ILahoz, AgustinCarretero, JulianShimamura, Takeshi
- [25] Small cell lung cancer transformation and tumor heterogeneity after sequential targeted therapy and immunotherapy in EGFR-mutant non-small cell lung cancer: A case reportFRONTIERS IN ONCOLOGY, 2022, 12Yang, Meng-HangYu, JiaCai, Chen-LeiLi, Wei
- [26] EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case ReportONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (12)Martinez-Hernandez, Maria F.Lara-Mejia, LuisIzquierdo-Tolosa, CarlosCabrera-Miranda, LuisArrieta, Oscar
- [27] Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung CancerFRONTIERS IN GENETICS, 2020, 11Shaurova, TatianaZhang, LetianGoodrich, David W.Hershberger, Pamela A.
- [28] Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapyLUNG CANCER, 2019, 138 : 52 - 57Shen, Chia-, IHuang, Hsu-ChingChiang, Chi-LuLuo, Yung-HungShiao, Tsu-HuiChiu, Chao-Hua
- [29] A Phase 1 Study of Erlotinib and Ruxolitinib in Patients with EGFR-Mutant Lung Cancers and Acquired Resistance to Erlotinib TherapyJOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S321 - S321Yu, HelenaPerez, Leslie A.Sima, Camelia S.Li, Bob T.Smith-Marrone, StephanieIqbal, AfsheenPaik, PaulDrilon, AlexanderKris, Markg.Bromberg, JacquelineRiely, Gregory J.
- [30] Selective translational activation of PBK (PDZ- binding kinase) reveals a molecular vulnerability of drug-tolerant persister cells to targeted therapies in EGFR-mutant lung adenocarcinomaCANCER RESEARCH, 2024, 84 (06)Leonce, CamilleDesage, Anne-LaureMourksi, Nour El-HoudaDe Souza, GenevieveVanbervliet, BeatriceCharrondiere, CamilleNicq, ConstanceNeri, JeremySwalduz, AurelieTonon, LaurieCumunel, EricGadot, NicolasIchim, GabrielDiaz, Jean-JacquesLovly, ChristineMazieres, JulienTabutin, MayeulPerol, MauriceLantuejoul, SylvieCalvayrac, OlivierForest, FabienMarcel, VirginieSaintigny, PierreOrtiz-Cuaran, Sandra